Benzinga | Oct 11, 2021 07:46AM EDT

SVB Leerink Upgrades ChemoCentryx to Outperform, Raises Price Target to $64

SVB Leerink analyst Joseph Schwartz upgrades ChemoCentryx (NASDAQ:CCXI) from Market Perform to Outperform and raises the price target from $17 to $64.